Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.44 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5561332 | 0.92 | MAP2K1 (0.46) | MAP2K1MAP2K2NPC1 | |
| SCHEMBL5559787 | 0.91 | MAP2K1 (0.41) | MAP2K1MAP2K2 | |
| SCHEMBL5554653 | 0.87 | MAP2K1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL5560026 | 0.86 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL5559985 | 0.86 | MAP2K1 (0.47) | MAP2K1MAP2K2 | |
| SCHEMBL5559814 | 0.86 | MAP2K1 (0.42) | MAP2K1MAP2K2 | |
| SCHEMBL5561069 | 0.85 | MAP2K1 (0.46) | MAP2K1MAP2K2 | |
| SCHEMBL5560210 | 0.85 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL5561592 | 0.85 | MAP2K1 (0.49) | MAP2K1MAP2K2 | |
| SCHEMBL5560829 | 0.82 | MAP2K1 (0.52) | MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682138-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1682138-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005051301-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |